BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 27370570)

  • 1. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.
    Kallifatidis G; Hoy JJ; Lokeshwar BL
    Semin Cancer Biol; 2016 Oct; 40-41():160-169. PubMed ID: 27370570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.
    Yarla NS; Bishayee A; Sethi G; Reddanna P; Kalle AM; Dhananjaya BL; Dowluru KS; Chintala R; Duddukuri GR
    Semin Cancer Biol; 2016 Oct; 40-41():48-81. PubMed ID: 26853158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.
    Bak MJ; Das Gupta S; Wahler J; Suh N
    Semin Cancer Biol; 2016 Oct; 40-41():170-191. PubMed ID: 27016037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells.
    Lin FM; Chen LR; Lin EH; Ke FC; Chen HY; Tsai MJ; Hsiao PW
    Carcinogenesis; 2007 Dec; 28(12):2521-9. PubMed ID: 17942463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer chemoprevention by silibinin: bench to bedside.
    Singh RP; Agarwal R
    Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.
    Fontana F; Raimondi M; Marzagalli M; Di Domizio A; Limonta P
    Cells; 2020 Feb; 9(2):. PubMed ID: 32085497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactive natural products in cancer prevention and therapy: Progress and promise.
    Bishayee A; Sethi G
    Semin Cancer Biol; 2016 Oct; 40-41():1-3. PubMed ID: 27565447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of novel agents for prostate cancer chemoprevention.
    Singh RP; Agarwal R
    Endocr Relat Cancer; 2006 Sep; 13(3):751-78. PubMed ID: 16954429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
    Bishop JL; Davies A; Ketola K; Zoubeidi A
    Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
    Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
    Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of prostate cancer: current status and future directions.
    Lieberman R
    Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemopreventive Potential of Ethanolic Extracts of Luobuma Leaves (Apocynum venetum L.) in Androgen Insensitive Prostate Cancer.
    Huang SP; Ho TM; Yang CW; Chang YJ; Chen JF; Shaw NS; Horng JC; Hsu SL; Liao MY; Wu LC; Ho JA
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28846663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
    Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
    Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.